Fecal Microbiota Transplant for Clostridium Difficile Infection in a Pregnant Patient
Overview
Affiliations
Background: Clostridium difficile infection has been associated with negative outcomes in the general population and in pregnant patients. Fecal microbiota transplant has become the standard for treatment of recurrent as well as refractory C difficile infection.
Case: We present a case of a 28-year-old pregnant woman who presented with recurrent C difficile infection despite treatment with vancomycin and fidaxomicin and underwent a successful fecal microbiota transplant through colonoscopy at 18 weeks of gestation. She no longer required antibiotics for the remainder of her pregnancy to treat C difficile and had a term vaginal delivery at 39 weeks of gestation.
Conclusion: Our pregnant patient tolerated and responded to a fecal microbiota transplant for treatment of recurrent C difficile infection. Future large-scale studies are needed to determine the efficacy, safety, and long-term effects of manipulating the microbiome in pregnant patients and the neonates.
Wang H, Deng F, Luo M, Wang X Front Immunol. 2024; 15:1417003.
PMID: 39640265 PMC: 11619044. DOI: 10.3389/fimmu.2024.1417003.
Karimi M, Shirsalimi N, Hashempour Z, Omran H, Sedighi E, Beigi F Front Immunol. 2024; 15:1439176.
PMID: 39391303 PMC: 11464302. DOI: 10.3389/fimmu.2024.1439176.
Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffre M Clin Microbiol Rev. 2024; 37(2):e0013523.
PMID: 38421181 PMC: 11324037. DOI: 10.1128/cmr.00135-23.
DuPont H, Salge M Antibiotics (Basel). 2023; 12(11).
PMID: 37998819 PMC: 10668833. DOI: 10.3390/antibiotics12111617.
Development of Gut Microbiota in the First 1000 Days after Birth and Potential Interventions.
Pantazi A, Balasa A, Mihai C, Chisnoiu T, Lupu V, Kassim M Nutrients. 2023; 15(16).
PMID: 37630837 PMC: 10457741. DOI: 10.3390/nu15163647.